Tolvaptan for hyponatremia with preserved sodium pool in critically ill patients

详细信息    查看全文

• 作者：Michele Umbrello ; Elena S. Mantovani ; Paolo Formenti…
• 关键词：Hyponatremia ; Critical illness ; Tolvaptan
• 刊名：Annals of Intensive Care
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：6
• 期：1
• 全文大小：937 KB
• 参考文献：1.Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med. 2009;122(9):857–65. doi:10.​1016/​j.​amjmed.​2009.​01.​027 .PubMedCentral CrossRef PubMed
  2.Bennani SL, Abouqal R, Zeggwagh AA, Madani N, Abidi K, Zekraoui A, et al. Incidence, causes and prognostic factors of hyponatremia in intensive care. Rev Med Interne. 2003;24(4):224–9.CrossRef PubMed
  3.Funk GC, Lindner G, Druml W, Metnitz B, Schwarz C, Bauer P, et al. Incidence and prognosis of dysnatremias present on ICU admission. Intensive Care Med. 2010;36(2):304–11. doi:10.​1007/​s00134-009-1692-0 .CrossRef PubMed
  4.Stelfox HT, Ahmed SB, Khandwala F, Zygun D, Shahpori R, Laupland K. The epidemiology of intensive care unit-acquired hyponatraemia and hypernatraemia in medical-surgical intensive care units. Crit Care. 2008;12(6):R162. doi:10.​1186/​cc7162 .PubMedCentral CrossRef PubMed
  5.Greenberg A, Verbalis JG, Amin AN, Burst VR, Chiodo JA 3rd, Chiong JR, et al. Current treatment practice and outcomes. Report of the hyponatremia registry. Kidney Int. 2015;88(1):167–77. doi:10.​1038/​ki.​2015.​4 .PubMedCentral CrossRef PubMed
  6.Sterns RH. Disorders of plasma sodium–causes, consequences, and correction. N Engl J Med. 2015;372(1):55–65. doi:10.​1056/​NEJMra1404489 .CrossRef PubMed
  7.Robertson GL. Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis. Am J Med. 2006;119(7 Suppl 1):S36–42. doi:10.​1016/​j.​amjmed.​2006.​05.​006 .CrossRef PubMed
  8.Adler SM, Verbalis JG. Disorders of body water homeostasis in critical illness. Endocrinol Metab Clin North Am. 2006;35(4):873–94. doi:10.​1016/​j.​ecl.​2006.​09.​011 .CrossRef PubMed
  9.Schrier RW, Berl T. Nonosmolar factors affecting renal water excretion (first of two parts). N Engl J Med. 1975;292(2):81–8. doi:10.​1056/​NEJM197501092920​207 .CrossRef PubMed
  10.Palm C, Pistrosch F, Herbrig K, Gross P. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia. Am J Med. 2006;119(7 Suppl 1):S87–92. doi:10.​1016/​j.​amjmed.​2006.​05.​014 .CrossRef PubMed
  11.Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126(10 Suppl 1):S1–42. doi:10.​1016/​j.​amjmed.​2013.​07.​006 .CrossRef PubMed
  12.Decaux G, Unger J, Brimioulle S, Mockel J. Hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone. Rapid correction with urea, sodium chloride, and water restriction therapy. JAMA. 1982;247(4):471–4.CrossRef PubMed
  13.Hantman D, Rossier B, Zohlman R, Schrier R. Rapid correction of hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone. An alternative treatment to hypertonic saline. Ann Intern Med. 1973;78(6):870–5.CrossRef PubMed
  14.Cherrill DA, Stote RM, Birge JR, Singer I. Demeclocycline treatment in the syndrome of inappropriate antidiuretic hormone secretion. Ann Intern Med. 1975;83(5):654–6.CrossRef PubMed
  15.Decaux G, Unger J, Mockel J. Urea therapy for inappropriate antidiuretic hormone secretion from tuberculous meningitis. JAMA. 1980;244(6):589–90.CrossRef PubMed
  16.Soupart A, Decaux G. Therapeutic recommendations for management of severe hyponatremia: current concepts on pathogenesis and prevention of neurologic complications. Clin Nephrol. 1996;46(3):149–69.PubMed
  17.Jaber BL, Almarzouqi L, Borgi L, Seabra SF, Balk EM, Madias NE. Short-term efficacy and safety of vasopressin receptor antagonists for treatment of hyponatremia. Am J Med. 2011;124(10):977. doi:10.​1016/​j.​amjmed.​2011.​04.​028 (e1–9).PubMedCentral CrossRef PubMed
  18.Decaux G, Waterlot Y, Genette F, Hallemans R, Demanet JC. Inappropriate secretion of antidiuretic hormone treated with frusemide. Br Med J (Clin Res Ed). 1982;285(6335):89–90.CrossRef
  19.Greenberg A. Diuretic complications. Am J Med Sci. 2000;319(1):10–24.CrossRef PubMed
  20.Zietse R, van der Lubbe N, Hoorn EJ. Current and future treatment options in SIADH. NDT plus. 2009;2(Suppl_3):iii12–9. doi:10.​1093/​ndtplus/​sfp154 .PubMedCentral PubMed
  21.Decaux G, Andres C, Gankam Kengne F, Soupart A. Treatment of euvolemic hyponatremia in the intensive care unit by urea. Crit Care. 2010;14(5):R184. doi:10.​1186/​cc9292 .PubMedCentral CrossRef PubMed
  22.Berl T. Vasopressin antagonists. N Engl J Med. 2015;372(23):2207–16. doi:10.​1056/​NEJMra1403672 .CrossRef PubMed
  23.Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T, et al. Urine sodium excretion after tolvaptan administration is dependent upon baseline serum sodium levels: a possible explanation for the improvement of hyponatremia with scarce chance of hypernatremia by a vasopressin receptor antagonist. Int Heart J. 2014;55(2):131–7.CrossRef PubMed
  24.Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355(20):2099–112. doi:10.​1056/​NEJMoa065181 .CrossRef PubMed
  25.Cyr PL, Slawsky KA, Olchanski N, Krasa HB, Goss TF, Zimmer C, et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. Am J Health Syst Pharm. 2011;68(4):328–33. doi:10.​2146/​ajhp100217 .CrossRef PubMed
  26.Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297(12):1332–43. doi:10.​1001/​jama.​297.​12.​1332 .CrossRef PubMed
  27.Rozen-Zvi B, Yahav D, Gheorghiade M, Korzets A, Leibovici L, Gafter U. Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis. Am J Kidney Dis. 2010;56(2):325–37. doi:10.​1053/​j.​ajkd.​2010.​01.​013 .CrossRef PubMed
  28.Verrua E, Mantovani G, Ferrante E, Noto A, Sala E, Malchiodi E, et al. Severe water intoxication secondary to the concomitant intake of non-steroidal anti-inflammatory drugs and desmopressin: a case report and review of the literature. Hormones (Athens). 2013;12(1):135–41.
  29.Mantovani E, Pirrone M, Spanu P, Albicini M, Gandola A, Ottolina D, et al. Hypo-osmolar fluid absorption in endoscopic resection: a new pharmacological approach. Minerva Anestesiol. 2015;81(5):591–2.PubMed
  30.Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med. 1967;42(5):790–806.CrossRef PubMed
  31.Verbalis JG, Zeltser D, Smith N, Barve A, Andoh M. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clin Endocrinol. 2008;69(1):159–68. doi:10.​1111/​j.​1365-2265.​2007.​03149.​x .CrossRef
  32.Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007;27(5):447–57. doi:10.​1159/​000106456 .CrossRef PubMed
  33.Velez JC, Dopson SJ, Sanders DS, Delay TA, Arthur JM. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience. Nephrol Dial Transplant. 2010;25(5):1524–31. doi:10.​1093/​ndt/​gfp731 .CrossRef PubMed
  34.Nguyen MK, Kurtz I. Derivation of a new formula for calculating urinary electrolyte-free water clearance based on the Edelman equation. Am J Physiol Renal Physiol. 2005;288(1):F1–7. doi:10.​1152/​ajprenal.​00259.​2004 .CrossRef PubMed
  35.Hall JE. Guyton and Hall Textbook of Medical Physiology. 12th ed. Philadelphia: Saunders; 2011.
  36.Haussinger D, Roth E, Lang F, Gerok W. Cellular hydration state: an important determinant of protein catabolism in health and disease. Lancet. 1993;341(8856):1330–2.CrossRef PubMed
  37.Wald R, Jaber BL, Price LL, Upadhyay A, Madias NE. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med. 2010;170(3):294–302. doi:10.​1001/​archinternmed.​2009.​513 .CrossRef PubMed
  38.Friedman B, Cirulli J. Hyponatremia in critical care patients: frequency, outcome, characteristics, and treatment with the vasopressin V2-receptor antagonist tolvaptan. J Crit Care. 2013;28(2):219. doi:10.​1016/​j.​jcrc.​2012.​06.​001 (e1–12).CrossRef PubMed
  39.Dasta JF, Chiong JR, Christian R, Lin J. Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials. Hosp Pract (1995). 2012;40(1):7–14. doi:10.​3810/​hp.​2012.​02.​942 .CrossRef
  40.Naidech AM, Paparello J, Liebling SM, Bassin SL, Levasseur K, Alberts MJ, et al. Use of Conivaptan (Vaprisol) for hyponatremic neuro-ICU patients. Neurocrit Care. 2010;13(1):57–61. doi:10.​1007/​s12028-010-9379-5 .CrossRef PubMed
  41.Galton C, Deem S, Yanez ND, Souter M, Chesnut R, Dagal A, et al. Open-label randomized trial of the safety and efficacy of a single dose conivaptan to raise serum sodium in patients with traumatic brain injury. Neurocrit Care. 2011;14(3):354–60. doi:10.​1007/​s12028-011-9525-8 .CrossRef PubMed
  42.Iapichino G. Low hemoglobin level with low oncotic pressure in critically ill patients. Is it a safe strategy?. Minerva Anestesiol. 2015.
  43.Iapichino G, Pesenti A, Radrizzani D, Solca M, Pelizzola A, Gattinoni L. Nutritional support to long-term anesthetized and curarized patients under extracorporeal respiratory assist for terminal pulmonary failure. JPEN J Parenter Enteral Nutr. 1983;7(1):50–4.CrossRef PubMed
  44.Mistraletti G, Sabbatini G, Taverna M, Figini MA, Umbrello M, Magni P, et al. Pharmacokinetics of orally administered melatonin in critically ill patients. J Pineal Res. 2010;48(2):142–7. doi:10.​1111/​j.​1600-079X.​2009.​00737.​x .CrossRef PubMed
  45.Metzger BL, DeVita MV, Michelis MF. Observations regarding the use of the aquaretic agent conivaptan for treatment of hyponatremia. Int Urol Nephrol. 2008;40(3):725–30. doi:10.​1007/​s11255-008-9353-8 .CrossRef PubMed
  46.Decaux G, Genette F, Mockel J. Hypouremia in the syndrome of inappropriate secretion of antidiuretic hormone. Ann Intern Med. 1980;93(5):716–7.CrossRef PubMed
  47.Verbalis JG. Pathogenesis of hyponatremia in an experimental model of the syndrome of inappropriate antidiuresis. Am J physiol. 1994;267(6 Pt 2):R1617–25.PubMed
  
• 作者单位：Michele Umbrello (1) (2)
  Elena S. Mantovani (1)
  Paolo Formenti (1)
  Claudia Casiraghi (2)
  Davide Ottolina (2)
  Martina Taverna (2)
  Angelo Pezzi (1)
  Giovanni Mistraletti (1) (2)
  Gaetano Iapichino (1) (2)
  
  1. Unità Operativa di Anestesia e Rianimazione, Azienda Ospedaliera San Paolo-Polo Universitario, Via A. Di Rudinì, 8, 20142, Milan, Italy
  2. Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Milan, Italy
  
• 刊物主题：Intensive / Critical Care Medicine; Emergency Medicine; Anesthesiology;
• 出版者：Springer Paris
• ISSN：2110-5820

文摘

Background Hyponatremia is the most common electrolyte disturbance in hospitalized patients, and it represents a well-established risk factor for ICU/hospital mortality. The majority of hyponatremic states are associated with elevated arginine vasopressin levels and a preserved sodium pool. Conventional treatment is either not pathophysiologically oriented or of limited effectiveness. The aim of the present study is to investigate the use of enteral Tolvaptan in critically ill hyponatremic patients.